HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Neutral rating on Lyell Immunopharma (NASDAQ:LYEL) and maintained a $1 price target.
October 28, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating on Lyell Immunopharma and maintained a $1 price target, indicating no expected significant short-term price movement.
The reiteration of a Neutral rating and maintenance of a $1 price target by HC Wainwright & Co. suggests that the analyst does not foresee significant changes in Lyell Immunopharma's stock price in the short term. This indicates stability rather than a positive or negative movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100